⚕️ The information below is for educational purposes only. It is not intended as a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.
Consult your healthcare provider before starting any medication.
When your doctor recommends GLP-1 therapy, "GLP-1 medication" is not a single drug — it's a growing class with meaningfully different options. In India, patients now have access to multiple GLP-1 receptor agonists (and one dual GIP/GLP-1 agonist), each with distinct weight-loss efficacy, costs, injection schedules, and availability profiles.
This guide explains every GLP-1 class medication currently in use in India, provides a head-to-head comparison, and helps you prepare for the conversation with your doctor about which one is right for you.
Manufacturer: Novo Nordisk Mechanism: Pure GLP-1 receptor agonist Injection frequency: Once weekly subcutaneous injection (or once daily oral as Rybelsus) Available doses: Ozempic: 0.25 mg, 0.5 mg, 1 mg, 2 mg | Wegovy: titrated up to 2.4 mg over 16 weeks
Semaglutide is the most extensively studied GLP-1 drug globally and is the most commonly prescribed in India. Ozempic is approved for type 2 diabetes management; Wegovy is approved specifically for chronic weight management in people with obesity.
Approximate cost in India (2025):
Clinical weight loss: STEP 1 trial — average 14.9% body weight reduction at 68 weeks on 2.4 mg weekly
Strengths: Extensive research data; once-weekly convenience; widely available across India; oral option (Rybelsus) for needle-averse patients Limitations: High cost; Wegovy requires grey-market import; nausea common during dose escalation
Manufacturer: Eli Lilly Mechanism: Dual GIP + GLP-1 receptor agonist — acts on two incretin pathways simultaneously Injection frequency: Once weekly subcutaneous injection Available doses: 2.5 mg → 5 mg → 7.5 mg → 10 mg → 12.5 mg → 15 mg (titrated monthly)
Tirzepatide (Mounjaro) is the newest and most potent option available to Indian patients. By activating both GLP-1 and GIP receptors, it achieves greater weight loss than any previous GLP-1 medication in head-to-head trial data.
Approximate cost in India (2025):
Clinical weight loss: SURMOUNT-1 trial — average 20.9% body weight reduction at 72 weeks on 15 mg weekly — the highest recorded for any approved medication
Strengths: Greatest weight loss of any option; once weekly; increasingly available in India; significant HbA1c reduction for diabetes Limitations: Most expensive; newer drug with less long-term safety data; cold-chain reliability varies; risk of counterfeit products when imported
Manufacturer: Eli Lilly Mechanism: Pure GLP-1 receptor agonist Injection frequency: Once weekly subcutaneous injection Available doses: 0.75 mg, 1.5 mg, 3 mg, 4.5 mg Approved use: Type 2 diabetes management (not approved in India for weight loss alone)
Dulaglutide (Trulicity) was one of the first GLP-1 medications widely available in India and remains the most affordable once-weekly option. It has robust cardiovascular outcome data (REWIND trial, 2019) and a notably user-friendly autoinjector pen that hides the needle entirely.
Approximate cost in India (2025):
Clinical weight loss: AWARD trials — average 3–5% body weight reduction — meaningful but considerably less than semaglutide or tirzepatide
Strengths: Most affordable once-weekly option in India; autoinjector pen is simplest to use; widely available at pharmacy chains; strong cardiovascular outcome data; lower nausea rate than semaglutide Limitations: Substantially less weight loss than semaglutide or tirzepatide; not approved for weight loss alone in India; limited dose escalation ceiling
Manufacturer: Novo Nordisk Mechanism: Pure GLP-1 receptor agonist Injection frequency: Once daily subcutaneous injection — the only daily option in this class Available doses: Victoza: 0.6 mg → 1.2 mg → 1.8 mg | Saxenda: 0.6 mg → 3 mg (titrated weekly)
Liraglutide was the original GLP-1 medication and carries the longest safety record of any drug in this class. Victoza has been used in India for type 2 diabetes for over a decade. It requires daily injection, making it less convenient than once-weekly options, and produces less weight loss than semaglutide or tirzepatide.
Approximate cost in India (2025):
Clinical weight loss: SCALE trial — average 5–8% body weight at 56 weeks on 3 mg daily
Strengths: Longest safety record; most endocrinologists in India have extensive prescribing experience; strong cardiovascular data (LEADER trial, 2016); widely available Limitations: Daily injection significantly less convenient than weekly options; less weight loss than semaglutide or tirzepatide; Saxenda has limited availability in India
| Feature | Semaglutide | Tirzepatide | Dulaglutide | Liraglutide |
|---|---|---|---|---|
| Brand names | Ozempic / Wegovy | Mounjaro | Trulicity | Victoza / Saxenda |
| Injection frequency | Once weekly | Once weekly | Once weekly | Once daily |
| Peak weight loss | 10–15% | 15–22% | 3–5% | 5–8% |
| HbA1c reduction | Excellent | Excellent | Good | Good |
| Monthly cost (India) | ₹10,000–22,000 | ₹13,000–18,000 | ₹4,000–6,500 | ₹8,000–15,000 |
| Pharmacy availability | Wide | Limited (often imported) | Wide | Wide (Victoza); Limited (Saxenda) |
| Key CV outcome trial | SUSTAIN-6 / SELECT | SURPASS-CVOT | REWIND | LEADER |
| Nausea frequency | Moderate | Moderate | Lower | Moderate |
| Device ease of use | Good (FlexTouch pen) | Good (AutoInjector) | Excellent (simplest pen) | Good (daily pen) |
There is no universally "best" GLP-1 — the right choice depends on your specific goals, health situation, and budget. These questions will help guide the conversation:
1. Is my primary goal diabetes control or weight loss? All four medications reduce HbA1c. For maximum weight loss, semaglutide 2.4 mg or tirzepatide are superior. For type 2 diabetes control where moderate weight loss is acceptable, dulaglutide offers the most affordable once-weekly option.
2. What can I afford long-term? GLP-1 therapy typically needs to continue indefinitely — weight often returns when stopped. Budget matters enormously. Dulaglutide at ₹4,000–6,500/month is dramatically more affordable than semaglutide at ₹10,000–22,000/month.
3. Do I have a history of cardiovascular disease? All four medications have positive cardiovascular outcome trial data. Dulaglutide (REWIND) and liraglutide (LEADER) have particularly extensive cardiovascular safety data, while semaglutide's SELECT trial in 2023 showed a 20% reduction in major cardiovascular events.
4. How important is injection frequency? Once-weekly injections (semaglutide, tirzepatide, dulaglutide) have better adherence data than daily injections (liraglutide). If you travel frequently or have variable schedules, once-weekly is more forgiving.
5. How experienced is my doctor with this specific medication? In India, dulaglutide (Trulicity) and liraglutide (Victoza) have the longest prescribing history, and most endocrinologists are highly familiar with them. Semaglutide expertise has grown rapidly. Tirzepatide is newer and prescribing experience varies by city and hospital.
Several Indian pharmaceutical companies (Cipla, Sun Pharma, Biocon, and others) are developing or have launched generic semaglutide. As of 2025, the Indian generic market is in early stages. Some generics are available at significantly reduced prices. Before switching to a generic, discuss bioequivalence data with your doctor and ensure purchase from a licensed pharmacy with verifiable cold-chain storage.
Can I switch from dulaglutide to semaglutide for more weight loss?
Yes — this is a common clinical transition when a patient has achieved reasonable diabetes control on dulaglutide but wants greater weight loss. No washout period is required. Your doctor will typically start semaglutide at 0.25 mg the week after stopping dulaglutide and titrate upward.
Is tirzepatide worth the extra cost over semaglutide?
For patients with significant obesity (BMI > 35) who have not achieved adequate weight loss on semaglutide, tirzepatide's superior efficacy may justify the higher cost. For patients primarily managing type 2 diabetes where weight loss is secondary, the cost difference is harder to justify.
Is it safe to buy imported Wegovy or Mounjaro through online pharmacies?
This carries real risks: counterfeit products, cold-chain breaches, and unverified potency. Only purchase from licensed pharmacies with a valid prescription and ask specifically about cold-chain documentation. Refer to guidance on counterfeit GLP-1 medications on this site.
When will newer medications like oral semaglutide at higher doses or oral tirzepatide be available in India?
Several next-generation GLP-1 agents are in late-stage trials globally. Indian regulatory approval typically follows US/EU approval by 1–3 years. Consult your endocrinologist for the latest information.
This article is for informational purposes only. Consult your healthcare provider before starting any medication.
